Denali Therapeutics (DNLI) EBT Margin (2018 - 2023)
Denali Therapeutics' (DNLI) quarterly EBT Margin came in at 7841.59% in Q3 2023, down 478088.0% year-on-year from N/an in Q3 2022, and down 12676.92% on a QoQ basis from 62.35% in Q2 2023.
Denali Therapeutics (DNLI) EBT Margin (2018 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 6 years of EBT Margin data on file, last reported at 7841.59% in Q3 2023.
- On a quarterly basis, EBT Margin fell 478088.0% year-over-year to 7841.59% in Q3 2023; TTM through Jun 2024 was 33565.19%, a 3352685.0% decrease from a year earlier, with the FY2023 full-year figure at 43.93%, up 26633.0% from the prior year.
- EBT Margin for Q3 2023 stood at 7841.59%, down from 62.35% in the prior quarter.
- Over the last five years, EBT Margin for DNLI reached as high as 77.56% in Q4 2020 and fell as low as 109419.23% in Q1 2020.
- Historically, EBT Margin has averaged 7027.02% across 5 years, with a median of 927.28% in 2019.
- Across the five-year window, EBT Margin plunged 10849195 bps in 2020 and surged 10853510 bps in 2021, its largest moves.
- Year by year, EBT Margin stood at 3648.78% in 2019, then soared by 102 bps to 77.56% in 2020, then slumped by 301 bps to 155.87% in 2021, then slumped by 533 bps to 986.84% in 2022, then slumped by 695 bps to 7841.59% in 2023.
- Per Business Quant data, the three most recent EBT Margin figures were 7841.59% in Q3 2023, 62.35% in Q2 2023, and 320.93% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -7,841.59% |
| Jun 30, 2023 | 62.35% |
| Mar 31, 2023 | -320.93% |
| Dec 31, 2022 | -986.84% |
| Sep 30, 2022 | -3,060.71% |
| Jun 30, 2022 | -111.98% |
| Mar 31, 2022 | -164.01% |
| Dec 31, 2021 | -155.87% |
| Sep 30, 2021 | -1,600.53% |
| Jun 30, 2021 | -404.61% |
| Mar 31, 2021 | -884.13% |
| Dec 31, 2020 | 77.56% |
| Sep 30, 2020 | -619.64% |
| Jun 30, 2020 | -1,009.79% |
| Mar 31, 2020 | -109,419.23% |
| Dec 31, 2019 | -3,648.78% |
| Sep 30, 2019 | -1,066.15% |
| Jun 30, 2019 | -1,431.19% |
| Mar 31, 2019 | -927.28% |
| Dec 31, 2018 | 61.69% |